Cyclophosphamide

Eight mice were randomly divided into two groups: (i) normal immunity group (n = 4), (ii) immunocompromised group (n = 4). The immunocompromised group received an intraperitoneal injection of 200 mg/kg cyclophosphamide (MACKLIN Co., Ltd., Shanghai, China) 4 days before the experiment, 1 day before, and on the day of inoculation. After anesthetization with chloral hydrate (Krohne Co., Ltd., Chengdu, China) (0.25 mL/mouse intraperitoneally), the dorsal aspects of the mice were shaved with a razor blade, disinfected with 75% ethanol, and the exposed area was gently abraded with a sterile sandpaper until glistening. Following this, a 0.2 mm sterilized derma-roller was used to pierce channels in the prepared area to facilitate penetration of the fungal suspension. The site was then disinfected with 75% ethanol, and after drying, a suspension of 100 µL was applied and lightly rubbed into the abraded area with a sterile blade. Finally, the infected area was covered with a sterile transparent film dressing (Minnesota Mining Manufacturing Medical Equipment Co., Ltd., Shanghai, China).

The 5-HMF was purchased from Aladdin (batch number H2020020, >95% (Gas chromatography), containing 3–5% water as a stabilizer). N-acetophenazine was purchased from Aladdin (batch number L1909182), and cyclophosphamide (CP) was purchased from MACKLIN (batch number C11147187).